Sana Biotechnology
Sana Biotechnology is a hypoimmune cell-therapy company that suspended its oncology allogeneic CAR-T (SC262) in late 2025 and pivoted to type 1 diabetes and in vivo CAR-T (SG293).
SC262 (CD22 allogeneic CAR-T) development suspended and VIVID enrolment halted in November 2025. SG293 is a fusogen-delivered CD19 in vivo CAR-T candidate for oncology and autoimmunity; SC451 (islet cells) leads in T1D. Illustrates the industry shift from ex vivo allogeneic to in vivo approaches.
Pages like this
not linked directly; found by shared links- CompanyTScan Therapeutics
Shares In vivo CAR-T and the tag pivot.
- CompanyFate Therapeutics
Shares Qualify one iPSC master cell bank once for many off-the-shelf cell products, Allogeneic (off-the-shelf) cell therapy, CD19, Manufacturing cost and time for living and radioactive medicines.
- CompanyNkarta
Shares CD19, Diffuse large B-cell lymphoma and the tag pivot.
- IdeaNon-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route
Shares Allogeneic (off-the-shelf) cell therapy, CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma.
- CompanyUmoja Biopharma
Shares In vivo CAR-T, CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma.
- CompanyCaribou Biosciences
Shares Allogeneic (off-the-shelf) cell therapy, CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma.
- CompanyAllogene Therapeutics
Shares Allogeneic (off-the-shelf) cell therapy, CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma.
- IdeaIn vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma
Shares In vivo CAR-T, CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma.